Heliyon 8 (2022) e09045

Contents lists available at ScienceDirect

Heliyon

journal homepage: www.cell.com/heliyon

Research article

CellPress

Synthesis, α -glucosidase inhibition, α -amylase inhibition, and molecular docking studies of 3,3-di(indolyl)indolin-2-ones



Helivon

Mardi Santoso^{a,*}, Li Lin Ong^{b,c}, Nur Pasca Aijijiyah^a, First Ambar Wati^a, Azminah Azminah^d, Rose Malina Annuur^a, Arif Fadlan^a, Zaher M.A. Judeh^{c,e}

^a Department of Chemistry, Faculty of Science, Institut Teknologi Sepuluh Nopember, Sukolilo, Surabaya, 60111, Indonesia

^b NTU Institute for Health Technologies, Interdisciplinary Graduate School, Nanyang Technological University, Research Techno Plaza, XFrontiers Block, #02-07, 50

Nanyang Drive, 637553, Singapore

^c School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, N1.2–B1-14, 637459, Singapore

^d Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Surabaya, Surabaya, 60284, Indonesia

e Division of Chemistry & Biological Chemistry, School of Physical & Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, 637371, Singapore

ARTICLE INFO

Keywords: 3,3-Di(indolyl)indolin-2-ones Diabetes α-glucosidase inhibition α-amylase inhibition Docking studies

ABSTRACT

The synthesized 3,3-di(indolyl)indolin-2-ones **1a-p** showed desired higher α -glucosidase inhibitory activities and lower α -amylase inhibitory activities than standard drug acarbose. Particularly, compound **1i** showed favorable higher α -glucosidase % inhibition of 67 \pm 13 and lower α -amylase % inhibition of 51 \pm 4 in comparison to acarbose with % inhibition activities of 19 \pm 5 and 90 \pm 2, respectively. Docking studies of selected 3,3-di(indolyl)indolin-2-ones revealed key interactions with the active sites of both α -glucosidase and α -amylase, further supporting the observed % inhibitory activities. Furthermore, the binding energies are consistent with the % inhibition values. The results suggest that 3,3-di(indolyl)indolin-2-ones may be developed as suitable Alpha Glucosidase Inhibitors (AGIs) and the lower α -amylase activities should be advantageous to reduce the side effects exhibited by commercial AGIs.

1. Introduction

Diabetes mellitus is a metabolic disease associated with high levels of sugars in the blood (hyperglycemia) [1]. Diabetes Type 1 accounts for $\sim 10\%$ and occurs in patients whose pancreas is not able to produce enough insulin. Type 2 diabetes accounts for $\sim 90\%$ and occurs when the body cannot use the secreted insulin effectively [2, 3]. Diabetes causes severe problems including cardiovascular diseases, nephropathy, neuropathy, retinopathy, etc [2, 3].

There are several approaches to control hyperglycemia in the blood each with its advantages and disadvantages. Such approaches mainly enhance insulin availability or remove sugar more effectively [1, 2]. An effective approach to limit the amount of sugar entering the bloodstream is to uses α -glucosidase inhibitors (AGIs) [4] which inhibit the α -glucosidase enzyme. Unfortunately, commercial AGIs cause undesired strong inhibition of α -amylase enzymes and are associated with severe side effects. α -Amylase enzymes in the saliva and pancreatic juices hydrolyze α -1,4-glycosidic bonds of starch to simpler dextrins, disaccharides, and oligosaccharides [5, 6]. As the food travels to the small intestine, the brush border cells of the epithelium secrets α -glucosidase enzymes which hydrolyze disaccharides and oligosaccharides giving α -D-glucose that pass to the bloodstream [7]. Consequently, inhibition of α -glucosidase limits the amount of α -D-glucose that passes to the bloodstream [8]. Current commercial AGI drugs represented by Acarbose, Miglitol, and Voglibose are effective inhibitors of α -glucosidase. However, they cause flatulence, diarrhea, bloating, abdominal pain, and discomfort [4]. It is thought that the side-effects result from fermentation of undigested carbohydrates due to strong inhibition of α -amylase [9]. Therefore, it is desirable to design new selective AGIs having strong inhibition of α -glucosidase and low inhibition of α -amylase.

Indole-based compounds are abundant in the plant kingdom and show many bioactivities including antimalarial [10], antifungal [11], anticancer [12], antibacterial [12], anti-diabetic [13], antihelmintic [14] activities. Several indole-based drugs such as Sunitinib, indolidan, delaverdine, indomethacin, indoxole, and vinblastine are marketed for the treatment of various diseases while others are at various stages of clinical trials [15, 16, 17].

* Corresponding author. *E-mail addresses:* tsv09@chem.its.ac.id, tsv09@yahoo.com (M. Santoso).

https://doi.org/10.1016/j.heliyon.2022.e09045

Received 6 June 2021; Received in revised form 3 August 2021; Accepted 1 March 2022

2405-8440/© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Oxindoles also exhibit many activities including antiviral, antimicrobial, antifungal, anticancer, anti-inflammatory, antihypertensive, serotonergic, analgesic and sleep-inducing activities [17]. Oxindoles of the 3,3-di(indolyl)indolin-2-ones type (Scheme 1) show antidiabetic [18], antimicrobial [19], anticancer [20], and spermicidal [21] activities. Recently, Wang and co-workers [18] reported promising α -glucosidase inhibition activities of several 3,3-di(indolyl)indolin-2-ones. However, the authors did not examine the α -amylase inhibition activities which are important for developing next-generation AGIs having minimal gastrointestinal side-effects. They also did not elucidate the structure-activity relationship of 3,3-di(indolyl)indolin-2-ones with aromatic substituents as well as strongly donating and withdrawing moieties on inhibition of α -glucosidase. Therefore, at this stage, the overall inhibitory activity profile of 3,3-di(indolyl)indolin-2-ones remains unclear.

Herein, we report the synthesis of diverse 3,3-di(indolyl)indolin-2ones and examine their α -glucosidase and α -amylase activities to provide a clear understanding of their overall inhibition effectiveness. To complement our study, we also report molecular docking studies to elucidate the mechanism of action of these compounds.


2. Materials and methods

The starting materials, solvents, and reagents were purchased from Sigma-Aldrich, Merck, and Fluka, and were used without further purification unless stated. Thin-layer chromatography was performed on Merck 0.20 mm precoated silica gel aluminum plates (Kieselgel 60, F254) and visualized using a UV lamp operating at 245 nm. Melting points were measured using the Fischer-John apparatus and are uncorrected. Infrared spectra were recorded using KBr disc on FTIR Shimadzu 8400S. ¹H NMR spectra were recorded using Jeol JNM-ECA300 (300 MHz), Jeol JNM-ECS400 (400 MHz), Bruker Avance DPX 300 (300 MHz), or Hitachi R-1900 FT NMR (90 MHz). ¹³C NMR spectra were recorded at 75 MHz on Jeol JNM-ECS400 (400 MHz), and 75.47 MHz on a Bruker Avance DPX 300. Mass spectra were obtained using a Xevo G2-XS QTof, Hitachi QP-5000, or Waters LCT Premier XE instrument.

2.1. Chemistry

2.1.1. General procedure for the synthesis of 3,3-di(indolyl)indolin-2-one

A solution of the isatin or its alkyl derivative and indole or its alkyl derivative in methanol (\sim 100 ml per 1g of isatin) was treated with a



Reagents and conditions: (i) BF_3 or H_2SO_4 , MeOH, 2 h, 40-60 °C; (ii) MeI, or Etl or Me_2SO_4 , KOH, DMSO, 2 h, 0 °C to r.t

Scheme 1. Synthesis of 3,3-di(indolyl)indolin-2-ones 1a-p.

catalytic amount of BF₃ or H₂SO₄ (2–3 drops per 1 g of isatin) and stirred at 40–60 °C for 1–2 h. After completion of the reaction as indicated by TLC, the reaction mixture was diluted with ice-cold water (50 mL per 1g of isatin). The resulting precipitates were filtered under vacuum, washed with an excess of ice-cold water (3 x 50 mL), and then were dried under vacuum to give the pure product. This general procedure was used to prepare 3,3-di(indolyl)indolin-2-one derivatives (1a-1c, 1f, 1i-1p).

3,3-Di(1*H*-indole-3-yl)indolin-2-one **(1a)**: Isatin (0.30 g, 2.04 mmol) and indole (0.47 g, 4.00 mmol) reacted to give **1a** as white powder, 0.71 g, 97% yield), m.p. 320–321 °C (lit [22]. 317–319 °C). ¹H NMR (90 MHz, DMSO-*d*₆): δ 6.70–7.40 (m, 14H), 10.54 (s, 2H), 10.91 (s, 1H). Mass spectrum (EI): *m/z* 363 (M, 80%), 334 (100), 247 (10), 219 (50).

3,3-Di(1-methyl-1*H*-indole-3-yl)indolin-2-one **(1b)**: Isatin (0.25 g, 1.70 mmol) and 1-methylindole (0.44 g, 3.35 mmol) reacted to give **1b** as white powder (0.58 g, 88% yield), m.p. 329–330 °C (lit [23]. 330–332 °C). ¹H NMR (90 MHz, (CD₃)₂CO): δ 3.76 (s, 6H), 6.74–7.45 (m, 14H), 9.45 (bs, 1H). Mass spectrum (EI): *m*/z 392 (M+1, 10%), 391 (M, 60), 376 (5), 362 (100), 233 (20).

3,3-Di(1-ethyl-1*H*-indole-3-yl)indolin-2-one **(1c)**: Isatin (0.052 g, 0.35 mmol) and 1-ethylindole (0.10 g, 0.69 mmol) reacted to give **1c** as white powder (0.13 g, 93% yield), m.p. 340–341 °C (lit [24]. mp 273–275 °C). ¹H NMR (90 MHz, (CD₃)₂CO): δ 1.28 (t, *J* = 7.2 Hz, 6H), 4.14 (q, *J* = 7.2 Hz, 4H), 6.73–7.47 (m, 14H), 10.56 (s, 1H). Mass spectrum (EI): *m/z* 420 (M+1, 10%), 419 (M, 65), 390 (100), 275 (15), 247 (10).

3,3-Di(1*H*-indole-3-yl)-5-bromoindolin-2-one **(1f)**: 5-Bromoisatin (0.050 g, 0.22 mmol) and indole (0.050 g, 0.45 mmol) reacted to give **1f** as brown solid (0.090 g, 92% yield), m.p. 282–283 °C (lit [19]. 299–301 °C). ¹H NMR (400 MHz, (CD₃)₂SO): δ 6.80 (t, J = 7.3 Hz, 2H), 6.87 (s, 2H), 6.95 (d, J = 8.2 Hz, 1H), 7.01 (t, J = 7.2 Hz, 2H), 7.18 (d, J = 7.8 Hz, 2H), 7.28 (s, 1H), 7.35 (d, J = 8,0 Hz, 2H), 7.39 (d, J = 8.3 Hz, 1H), 10.74 (s, 1H), 10.99 (s, 2H). Mass spectrum (EI): m/z 443 (M, ⁸¹Br, 10%), 441 (M, ⁷⁹Br, 10), 327 (5), 325 (5), 299 (5), 297 (5), 44 (100).

3,3-Di(5-hydroxy-1*H*-indole-3-yl)-5-nitroindolin-2-one **(1i)**: 5-Nitroisatin (0.096 g, 0.50 mmol) and 5-hydroxyindole (0.13 g, 1.00 mmol) reacted, and after column chromatography (ethyl acetate:*n*-hexane, 2:1), gave **1i** as brown solid (0.15 g, 68 % yield), m.p. 302–303 °C. IR (KBr disk): 3524, 3349, 3117, 1697, 1626, 1605, 1582, 1528, 1468, 1338, 1202, 1062 cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆): δ 6.53 (dd, *J* = 8.4, *J* = 2.4 Hz, 4H), 6.57 (d, *J* = 2.4 Hz, 2H), 6.78 (d, *J* = 2.4 Hz, 2H), 7.12–7.16 (m, 3H), 7.90 (d, *J* = 2.0 Hz, 1H), 8.20 (dd, *J* = 8.4, *J* = 2.4 Hz, 1H), 8.52 (s, 2H), 10.72 (s, 2H), 11.20 (bs, 1H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 53.1, 105.1, 110.3, 112.2, 112.6, 120.5, 125.6, 125.7, 125.9, 126.7, 132.1, 136.0, 142.7, 148.4, 150.5, 179.5.

3,3-Di(1*H*-indole-3-yl)-5-nitroindolin-2-one **(1j)**: 5-Nitroisatin (0.072 g, 0.38 mmol) and indole (0.088 g, 0.75 mmol) reacted to give the **1j** as yellow solid (0.13 g, 87% yield), m.p. 272–273 °C (lit [22]. 281–282 °C). IR (KBr disc): 3385, 3123, 3059, 1709, 1620, 1528, 1481, 1456, 1420, 1340, 1246, 1215, 1175, 1129, 1086, 1013, 941 cm⁻¹. ¹H NMR (300 MHz, (CD₃)₂CO): δ 6.87 (t, J = 4.6 Hz, 2H), 7.05–7.09 (m, 4H), 7.07 (s, 1H), 7.32 (d, J = 9.1 Hz, 1H), 7.42 (d, J = 5.1 Hz, 4H), 7.44 (d, J = 4.8 Hz, 2H), 8,15 (d, J = 1.5 Hz, 1H), 8.27 (dd, J = 4.0, 1.5 Hz, 1H), 10.20 (bs, 1H), 10.29 (s, 2H). ¹³C NMR (75 MHz, (CD₃)₂CO): δ 53.9, 110.6, 112.6, 114.7, 119.8, 121.6, 121.9, 122.5, 125.6, 126.1, 126.9, 136.6, 138.5, 143.9, 148.6, 179.5. MS (ES): m/z calcd for C₂₄H₁₅N₄O₃, [M-H]⁻ 407.1144; Found 407.1124.

3,3-Di(1-methyl-1*H*-indole-3-yl)-5-nitroindolin-2-one (1k): 5-Nitroisatin (0.29 g, 1.51 mmol) and 1-methylindole (0.39 g, 2.97 mmol) reacted to give 1k as yellow solid (0.61 g, 94% yield), m.p. 291–292 °C (lit [25]. >300 °C). ¹H NMR (300 MHz, (CD₃)₂CO): δ 3.78 (s, 6H), 6.88 (t, *J* = 4.1 Hz, 2H), 7.00 (s, 2H), 7.12 (t, *J* = 4.6 Hz, 2H), 7.31 (d, *J* = 5.2 Hz, 1H), 7.37 (d, *J* = 4.8 Hz, 2H), 7.41 (d, *J* = 4.8 Hz, 2H), 8.12 (d, *J* = 1.5 Hz,1H), 8.26 (dd, *J* = 4.5, 1.4Hz, 1H), 10.29 (bs, 2H). ¹³C NMR (125 MHz, (CD₃)₂CO): δ 32.9, 53.7, 110.6, 110.6, 113.6, 119.7, 121.6, 122.1, 122.5, 126.1, 127.3, 129.8, 136.6, 138.9, 143.9, 148.6, 179.4. MS (ES): *m*/z calcd for C₂₆H₁₉N₄O₃, [M-H]⁻ 435.1457; Found 435.1436.

3,3-Di(1*H*-indole-3-yl)-1-benzyl-5-nitroindolin-2-one **(11)**: 1-Benzyl-5-nitroisatin (0.070 g, 0.25 mmol) and indole (0.060 g, 0.51 mmol) reacted to give **11** as a yellow solid (0.10 g, 83% yield), m.p. 237–238 °C. IR (KBr disc): 3458, 3352, 3125, 3061, 1711, 1603, 1518, 1487, 1454, 1335, 1211, 1173, 1105, 1080, 748 cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆): δ 5.09 (s, 2H), 6.74 (t, J = 7.6 Hz, 2H), 6.95 (d, J = 2.4 Hz, 2H), 7.01 (d, J = 7.6 Hz, 2H), 7.07 (d, J = 8.6 Hz, 2H), 7.28–7.37 (m, 8H), 8.00 (d, J = 2.4 Hz, 1H), 8.24 (dd, J = 8.6, 2.4 Hz, 1H), 11.09 (s, 2H). ¹³C NMR (400 MHz, DMSO-*d*₆): δ 43.9, 52.7, 110.2, 112.4, 113.0, 119.1, 120.4, 120.9, 121.8, 125.2, 125.8, 125.9, 128.2, 128.3, 129.3, 135.0, 136.3, 137.6, 143.4, 148.2, 177.9. HRMS (ES): *m*/z calcd for C₃₁H₂₁N₄O₃, [M-H]⁻ 497.1614; Found 497.1636.

3,3-Di(1*H*-indole-3-yl)-1-benzyl-5-bromoindolin-2-one **(1m)**: 1-Benzyl-5-bromoisatin (0.030 g, 0.10 mmol) and indole (0.020 g, 0.20 mmol) reacted to give **1m** as yellow solid (0.043 g, 81% yield), m.p. 188–189 °C (lit [19]. 268–270 °C). IR (KBr disc): 3428, 3356, 3131, 3063, 1699, 1603, 1546, 1479, 1454, 1422, 1341, 1242, 1213, 1173, 1101, 1065, 1013, 749 cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆): δ 5.00 (s, 2H), 6.74 (t, *J* = 8.0 Hz, 2H), 6.89 (d, *J* = 2.8 Hz, 2H), 7.01 (t, *J* = 7.6 Hz, 2H), 7.08 (t, *J* = 7.0 Hz, 3H), 7.26–7.45 (m, 10H), 11.03 (s, 2H). ¹³C NMR (400 MHz, DMSO-*d*₆): δ 43.6, 53.0, 112.0, 112.3, 113.7, 114.7, 119.0, 121.0, 121.7, 125.0, 125.9, 127.8, 128.1, 129.2, 131.3, 136.7, 136.7, 137.5, 141.6, 177.1. MS (ES): *m*/z calcd for C₃₁H₃₁N₃OBr, [M-H]⁻ 530.0868; Found 530.0910.

3,3-Di(1*H*-indole-3-yl)-1-(4-bromobenzyl)-5-bromoindolin-2-one **(1n)**: 1-(4-Bromobenzyl)-5-bromoisatin (0.19 g, 0.48 mmol) and indole (0.12 g, 1.02 mmol) reacted to give **1n** as ivory coloured solid (0.28 g, 97% yield), m.p. 248–249 °C. IR (KBr disc): 3416, 3287, 3056, 1715, 1601, 1537, 1422, 1333, 1244, 1206, 1167, 1101, 1071, 1013, 741 cm⁻¹. ¹H NMR (400 MHz, DMSO-*d*₆): δ 4.97 (s, 2H), 6.73 (t, *J* = 7.4 Hz, 2H), 6.87 (s, 2H), 7.00 (dd, *J* = 12.8, 8.0 Hz, 4H), 7.13 (d, *J* = 8.0 Hz, 1H), 7.28 (d, *J* = 8.0 Hz, 2H), 7.35 (d, *J* = 7.4 Hz, 3H), 7.45 (d, *J* = 8.4 Hz, 1H), 7.49 (d, *J* = 8.0 Hz, 2H), 11.02 (s, 2H). ¹³C NMR (400 MHz, DMSO-*d*₆): δ 42.5, 52.4, 111.5, 111.9, 113.1, 114.3, 118.5, 120.5, 120.8, 121.2, 124.6, 125.4, 127.3, 130.0, 130.8, 131.6, 135.7, 136.1, 137.0, 140.9, 176.6. MS (ES): *m*/z calcd for C₃₁H₂₁N₃OBr₂, [M + Na]⁺ 633.9929; Found 633.9542.

3,3-Di(1*H*-indole-3-yl)-5-chloroindolin-2-one **(10)**: 5-Chloroisatin (0.051 g, 0.28 mmol) and indole (0.065 g, 0.56 mmol) reacted to give **10** as brown solid (0.10 g, 98% yield), m.p. 275–276 °C (lit [22]. 290–291 °C). ¹H NMR (90 MHz, CDCl₃): δ 6.81–7.42 (m, 13H), 10.70 (s, 1H), 10.98 (s, 2H). Mass spectrum (EI): m/z 399 (M, ³⁷Cl, 10%), 397 (M, ³⁵Cl, 30), 368 (15), 246 (50), 117 (35), 44 (100).

3,3'-Di(1-methyl-1*H*-indole-3-yl)-5-chloroindolin-2-one **(1p)**: 5-Chloroisatin (0.083 g, 0.46 mmol) and 1-methylindole (0.12 g, 0.92 mmol) reacted to give **1p** as pink solid (0.17 g, 89% yield), m.p. 278–279 °C (lit [26]. >300 °C). IR (KBr disc): 3223, 2932, 1717, 1616, 1541, 1476, 1429, 1371, 1333, 1290, 1248, 1200, 739 cm⁻¹. ¹H NMR (90 MHz, DMSO-*d*₆): δ 3.72 (s, 6H), 6.77–7.44 (m, 3H), 10.74 (s, 1H). Mass spectrum (EI): *m*/*z* 427 (M, ³⁷Cl, 5), 425 (M, ³⁵Cl, 15), 399 (30), 397 (10), 269 (9), 267 (3), 44 (100).

2.1.2. General procedures for the synthesis of substituted 3,3-di(indolyl) indolin-2-one through N-alkylation

A mixture of the 3,3-di(indolyl)indolin-2-one and freshly crushed KOH in anhydrous DMSO was stirred at room temperature for 1 h. After cooling to ice-bath temperature, the alkylating agent was added and the mixture was stirred further at room temperature for 1 h. After completion of the reaction as indicated by TLC, the reaction mixture was diluted with ice-cold water (\sim 50 mL per 0.5 mmol of starting indolin-2-one). The resulting precipitate was filtered under vacuum, washed with an excess of ice-cold water (3 x 50 mL), and dried to give the pure product. This general procedure was used to make compounds **1d**, **1e**, and **1g**.

3,3-Di(1-methyl-1*H*-indole-3-yl)-1-methylindolin-2-one (1d): A mixture of 1b (0.20 g, 0.51 mmol) and KOH (0.11 g, 1.96 mmol) in anhydrous DMSO (15 mL) reacted with methyl iodide (0.06 mL, 0.96

mmol) to give **1d** as white solid (0.19 g, 90% yield), m.p. 218–219 °C (lit [23]. 232–234 °C). ¹H NMR (CDCl₃): δ 3.32 (s, 3H), 3.66 (s, 6H); 6.82–7.48 (m, 14H). Mass spectrum (EI): *m*/*z* 406 (M+1, 30%), 405 (M, 100), 390 (10), 376 (90), 275 (40), 247 (70), 233 (20).

3,3-Di(1-ethyl-1*H*-indole-3-yl)-1-ethylindolin-2-one **(1e)**: A mixture of **1c** (0.10 g, 0.24 mmol) and KOH (0.066 g, 1.18 mmol) in anhydrous DMSO (10 mL) reacted with ethyl iodide (0.04 mL, 0.48 mmol) to give **1e** as white solid (0.10 g, 91% yield), m.p. 169–170 °C (lit [27]. 272–274 °C). ¹H NMR (CDCl₃): δ 1.23–1.29 (m, 9H), 3.83 (q, J = 6.0 Hz, 2H), 4.13 (q, J = 6.0 Hz, 4H), 6.83 (t, J = 9.0 Hz, 2H), 6.92 (s, 2H), 6.98–7.10 (m, 3H), 7.17–7.27 (m, 3H), 7.32 (d, J = 6.0 Hz, 2Hz), 7.43 (d, J = 9.0 Hz, 2H). Mass spectrum (EI): m/z 448 (M+1, 30%), 447 (M, 100), 418 (75), 404 (30), 390 (20), 303 (40), 275 (40), 247 (70), 233 (20).

3,3-Di(5-bromo-1-methyl-1*H*-indole-3-yl)-5-bromo-1-methylindolin-2-one **(1g)**: A mixture of 3,3-di(5-bromo-1-methyl-1*H*-indole-3-yl)-5-bromoindolin-2-one (0.030 g, 0.048 mmol) and KOH (0.036 g, 0.64 mmol) in anhydrous DMSO (15 mL) reacted with dimethyl sulfate (0.06 mL, 0.63 mmol) to give **1g** as light orange solid (0.029 g, 94% yield), m.p. 287–288 °C. IR (KBr disc): 2918, 1713, 1607, 1537, 1474, 1422, 1368, 1337, 1273, 1219, 1144, 1094, 1049, 789 cm^{-1.} ¹H NMR (500 MHz, CDCl₃): δ 3.25 (s, 3H), 3.73 (s, 6H), 7.02 (s, 2H), 7.21 (d, J = 8.4 Hz, 1H), 7.23 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 7.27 (d, J = 2.0 Hz, 1H), 7.31 (d, J = 2.0 Hz, 1H), 7.43 (d, J = 9.1 Hz, 2H), 7.59 (dd, J = 8.4, 2.0 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 26.5, 32.7, 51.7, 111.2, 111.6, 111.7, 112.4, 114.4, 122.5, 123.9, 127.2, 130.2, 131.2, 134.8, 136.2, 141.8, 175.9. Mass spectrum (ES): m/z calcd for C₂₇H₂₁Br₃N₃O, [M + H]⁺ 639.9235; Found 639.9280.

2.1.3. Reduction of 1j to 1h

3,3'-Di(1H-indole-3-yl)-5-5-aminoindolin-2-one (1h): A mixture of 1j (0.10 g, 0.25 mmol) and Pd/C (0.01 g) in ethanol (10 mL) was brought to reflux. To this mixture, a solution of hydrazine hydrate (0.49 mL, 0.01 mmol) in ethanol (10 mL) was added dropwise. The resulting mixture was heated to reflux for 90 min, allowed to cool and then diluted with THF (5 mL). The cooled mixture was filtered and the mother liquor was diluted with water (50 mL). The resulting precipitates were filtered under vacuum, washed with excess of ice-cold water (3 x 50 mL), dried over MgSO₄, purified by column chromatography (chloroform:ethyl acetate, 1:2) to give 1h as brown-yellow solid (0.068 g, 72% yield), m.p. 258–259 °C. IR (KBr disc): 3626, 3364, 3315, 3121, 3057, 1666, 1614, 1491, 1456, 1421, 1335, 1244, 1207, 1103, 1014 cm⁻¹. ¹H NMR (400 MHz, DMSO- d_6): δ 5.11 (bs 2H), 6.44 (dd, J =8.0, 2.0 Hz, 1H), 6.52 (s, 1H), 6.66 (d, J = 8.8 Hz, 1H), 6.75 (t, J = 7.6 Hz, 2H), 6.79 (d, J = 2.4 Hz, 2H), 6.97 (t, J = 7.2 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.30 (d, *J* = 7.6 Hz, 2H), 10.15 (s, 1H), 10.88 (s, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 53.4, 110.3, 112.0, 113.1, 114.0, 115.3, 118.6, 121.4, 121.5, 124.8, 126.3, 132.3, 136.0, 137.4, 142.8, 179.0. Mass spectrum (ES): m/z calcd for C₂₄H₁₉N₄O, $[M + H]^+$ 379.1559; Found 379.3989.

2.2. α -Glucosidase inhibition assay

In principle, Kang and co-workers method was used to examine the α -glucosidase inhibitory activity of the synthesized compounds [28]. In this method, a solution of 50 µg/mL final concentration was prepared for each compound in DMSO. 8 µL of this solution was added to 115 µL of 0.1 M sodium phosphate buffer pH 7.0 in a 96 well microtiter plate. To this mixture, 50 µL of α -glucosidase enzyme solution (0.5 U/mL of yeast α -glucosidase in buffer solution) was introduced. The 'Blank', was prepared similarly but 50 µL of buffer was added instead of the enzyme, and 8 µL of DMSO was added instead of the inhibitor. Positive control was also prepared in a similar fashion where no inhibitor is replaced by 8 µL of DMSO. Acarbose was used as the standard drug in this procedure. The microtiter plate was shaken for 15 min at 37 °C then 25 µL of 2.5 mM of 4-nitrophenyl β -D-glucopyranoside (PNPG) was introduced to each well. The plate was shaken for another 15 min at the same temperature and the

absorbance was measured at 405 nm. The percentage of inhibition was calculated as Eq. (1):

$$\left(\frac{(Abs_{positive\ control} - Abs_{compound})}{Abs_{positive\ control}}\right) \times 100\% \tag{1}$$

All measurements are performed in triplicates and the values are represented as mean \pm standard deviation.

2.3. α -Amylase inhibition assay

Phan and co-workers method was used for testing α -amylase inhibitory activity [29]. Solution corresponding to 50 µg/mL in DMSO was prepared. To each test tube, 50 µL of these test solutions, 100 µL of α -amylase (5U/mL of porcine pancreatic α -amylase in 0.05 sodium phosphate buffer pH 6.8) and 460 µL of 0.05 M sodium phosphate buffer pH 6.8 were added. 'Blank' and 'Positive Control' were prepared similarly but 50 µL of DMSO was added instead of the inhibitor. In the case of 'Blank', the enzyme solution was replaced by 100 µL of the buffer. Results were compared to Acarbose as the standard drug. The test tubes were shaken for 10 min at 37 $^\circ C$ whereupon 450 μL of 0.5% starch solution was added to each tube and the shaking continued for another 20 min. At this point, 500 µL of dinitro salicylic acid (DNSA) reagent was added to each tube. The tubes were introduced in a boiling water bath for 15 min and the absorbance was then measured at 540 nm. The 0.5% starch solution was prepared by dissolving 0.5 g of starch in 99.5 mL of buffer. The starch solution was heated in a boiling water bath for 5 min to ensure starch dissolved completely. The percentage inhibition was calculated using Eq. (1). All measurements were performed in triplicates and the values are represented as mean \pm standard deviation. Note that the DNSA solution is prepared by dissolving 1 g of DNSA in 50.0 mL of ultrapure water followed by slow addition of 30.0 g of sodium tartrate and 20.0 mL of 2N NaOH solution. Finally, the volume was topped up to 100 mL with ultrapure water.

2.4. Molecular docking

Docking simulations were performed to reveal the binding modes of 3,3-di(indolyl)indolin-2-ones **1a**, **1i**, and **1n** with α -glucosidase and α -amylase enzymes. The structure of the human lysosomal α -glucosidase [30] and human pancreatic α -amylase [31] was directly

downloaded from the protein data bank (PDBID: 5NN5 and 6OCN, respectively) and was optimized after removing the co-factors, water molecules, and heteroatoms. The structures of the ligands were directly drawn using MarvinSketch program [32]. The docking simulation was conducted using Autodock 4.2.6 software [33]. The docking center was set to be the center of protein and the docking pocket size was set to be large enough to cover the whole protein molecule. The docking results were visualized using Discovery studio (Dassault Systèmes, San Diego) [34].

3. Results and discussions

3.1. Synthesis of 3,3-di(indolyl)indolin-2-ones 1a-p

The route to synthesize 3,3-di(indolyl)indolin-2-ones 1a-p is shown in Scheme 1. The reaction between indoles 2 and isatins 3 in the presence of a catalytic amount of BF3 or H2SO4 at 40-60 °C afforded the desired products 1a-1c, 1f, and 1i-1p in high 68-97% yields within 2 h. Compounds 1d, 1e, and 1g were obtained conveniently in high 90-94% yields by alkylating their corresponding counterparts. The 3,3-di(indolyl) indolin-2-ones **1a-p** were characterized using MS, IR, ¹H NMR and ¹³C NMR and the spectral data were consistent with the structures and are typical for oxindole systems.¹⁸ For an illustrative example, the ¹H NMR spectrum of 1n recorded in DMSO-d6 showed 21 protons. Singlet signals at $\delta_{\rm H}$ 4.97 and 11.02 ppm were assigned to methylene group protons and -NH protons respectively. The ¹³C NMR spectrum showed signals at $\delta_{\rm C}$ 42.5 and 52.4 ppm correspond to a methylene carbon and a spiro carbon respectively, and a signal at $\delta_{\rm C}$ 176.6 ppm indicates the presence of carbonyl carbon. The IR spectrum of compound 1n showed peak at 1715 revealing the presence of lactam amide (-NH-CO-). MS data was acquired in the positive ionization mode, exhibited peak at m/z = 633.9542 $[M + Na]^+$.


3.2. α -Glucosidase and α -amylase inhibition studies

The α -glucosidase and α -amylase % inhibition activities of the synthesized 3,3-di(indolyl)indolin-2-ones **1a-p** along with that of acarbose as the positive standard drug are summarized in Table 1. In general, while the compounds showed high to excellent inhibition activities for both enzymes, they showed stronger α -glucosidase inhibitory activity and desired lower α -amylase inhibitory activity in comparison to standard AGI drug acarbose.

Table 1. Percentage inhibition of α-glucosidase and α-amylase by 3,3-di(indolyl)indolin-2-ones 1a-p with acarbose as the reference standard.

No	Indolin-2-one	\mathbb{R}^1	R^2	R ³	R^4/R^5	% α -glucosidase inhibition ^a	% α-amylase inhibition
1	1a	Н	Н	Н	Н	16 ± 6	92 ± 4
2	1b	Н	Н	CH ₃	Н	37 ± 11	81 ± 6
3	1c	Н	Н	CH_3CH_2	Н	73 ± 6	72 ± 5
4	1d	Н	Н	CH ₃	CH ₃	86 ± 7	77 ± 8
5	1e	Н	Н	CH_3CH_2	CH ₃ CH ₂	50 ± 11	74 ± 9
6	1f	Н	Br	Н	Н	76 ± 8	86 ± 10
7	1g	Br	Br	CH ₃	CH ₃	61 ± 1	79 ± 4
8	1h	Н	NH ₂	Н	Н	17 ± 3	79 ± 9
9	1i	OH	NO_2	Н	Н	67 ± 13	51 ± 4
10	1j	Н	NO ₂	Н	Н	79 ± 5	93 ± 6
11	1k	Н	NO ₂	CH ₃	Н	86 ± 6	91 ± 5
12	11	Н	NO ₂	Н	Benzyl	76 ± 8	86 ± 0
13	1m	Н	Br	Н	Benzyl	92 ± 3	80 ± 3
14	1n	Н	Br	Н	4-Br-benzyl	94 ± 3	73 ± 5
15	10	Н	Cl	Н	Н	83 ± 2	87 ± 6
16	1p	Н	Cl	CH ₃	Н	84 ± 2	81 ± 7
17	Acarbose ^a					19 ± 5	90 ± 2

 a Inhibition was measured at a concentration of 50 µg/ml. Inhibition values are expressed as means \pm SD; n = 3.









Figure 1. Binding interaction of (a) indolin-2-one 1a; (b) indolin-2-one 1i; and (c) indolin-2-one 1n in with α -glucosidase (PDB ID: 5NN5).

3.2.1. α -Glucosidase inhibition activities

All the compounds showed higher % α -glucosidase inhibition activities ranging from 37 ± 11 to 94 ± 3 in comparison to acarbose with % inhibition activity of 19 ± 5, all measured at a concentration of 50 µg/ml. Exceptions are compounds **1a** and **1h** which showed % inhibition activities of 16 ± 6 and 17 ± 3, respectively (Table 1, entries 1 and 8). Considering the compounds in Table 1, the type of substituent and their position played a role in the inhibition activities to different extents. Compound **1a** with no substituents showed the lowest % inhibition activity of 16 ± 6. In the study conducted by Wang *et.al.* [18], the same compound **1a** showed the lowest IC₅₀ value of 145.95 ± 0.46 µM. Introduction of a methyl moiety at the indole rings as in **1b** lead to doubling of the % inhibition activity to 37 ± 11 while the introduction of an ethyl moiety as in **1c** increases the activity to more than four folds to 73 ± 6. Interestingly, while the introduction of methyl moiety to the

oxindole ring increased the inhibition activity of **1d** to 86 ± 7 , the introduction of a corresponding ethyl moiety as in **1e** reduced the activity to 50 ± 11 . This unpredicted result underscores the effect of small structural changes on inhibitory activity. Compound **1f** with bromine moiety enhanced the % inhibition activity of its parent **1a** by five-folds from 16 ± 6 to 76 ± 8 . However, compound **1g** with the bromine at the same position but with another at the indole rings gave lower inhibition activity of 61 ± 1 in comparison to its parent **1d** with inhibition activity of 86 ± 7 . The introduction of strong electron-donating NH₂ group on the oxindole ring of **1a** to give **1h** did not significantly affect the % inhibition activity $(17 \pm 3 vs 16 \pm 6, entry 8 vs entry 1, Table 1)$. However, the introduction of additional OH groups on the indole rings of **1h** and replacing its NH₂ group with NO₂ group to give **1i**, significantly increased the % inhibition activity from 17 ± 3 to 67 ± 13 (Table 1, entry 8 vs entry 9). Additionally, stronger electron-withdrawing NO₂ groups of



(a)




Figure 2. Binding interaction of (a) indolin-2-one 1a, (b) indolin-2-one 1i, and (c) indolin-2-one 1n with α-amylase (PDB ID: 60CN).

1j increased its activity to almost five-fold (79 \pm 5 vs 16 \pm 6, Table 1, entry 10 vs entry 1). At this stage, we predicted that the introduction of *N*-alkyl substituents to **1j** will increase its inhibition activities. However, while compound **1k** with methyl substituents showed a moderate increase in the % inhibition activity to 86 \pm 6, compound **1l** with benzyl substituent decreased the % inhibition activity to 76 \pm 8 perhaps due to stearic effects which prevented better fitting with the enzyme active sites. A significant increase in the activity occurred by changing the strong electron-withdrawing NO₂ group of **1l** to bromine as in **1m** which showed % inhibition of 92 \pm 3, or related **1n** which showed % inhibition of 94 \pm 3. Replacement of bromine of **1f** with chlorine to get **1o** resulted in a small increase in the % inhibition activity (Table 1, entry 6 vs entry 15). Methylation of **1o** with to obtain **1p** did not increase the % inhibition activity.

3.2.2. α -Amylase inhibition activities

The tested compounds in Table 1 showed high to very high α -amylase % inhibition activities ranging from 72 ± 5 to 92 ± 4, except 1i which

showed a % inhibition value of 51 \pm 4, all measured at a concentration of 50 µg/ml. Overall, the differences in activities between structurally related compounds are not as pronounced as in the α -glucosidase case. Interestingly, compound 1a which showed the lowest α -glucosidase inhibitory activity exhibited one of the highest α -amylase % inhibition activity of 92 \pm 4. The inhibition activity varied with the size/number of the substituents. For example, as the size/number of the substituents increases in compounds 1a-e, the corresponding inhibition values decrease (Table 1, entries 1-5). The same is also observed for compounds 1f and 1g. The situation becomes ambiguous when we consider the effects of electron-withdrawing and donating substituents which gave no obvious trend. For example, the parent compound 1a showed very high % inhibition activity similar to compounds 1j with 93 ± 6 and 1k with 91 $\pm\,5$ having strong electron-withdrawing group NO_2 and donating methyl moieties. The inhibition values in Table 1 suggest that compounds 1a-h and **1j-p** have a similar mode of interactions with α -amylase enzymes and that mode is different in the case of 1i. As mentioned in the introduction section, lower α -amylase inhibition is desired to overcome the

gastrointestinal side-effects. Therefore, compound **1i** serves this purpose considering that it has the lowest α -amylase activity and high α -gluco-sidase activity.

3.3. Molecular docking studies

Docking simulations were performed on 3,3-di(indolyl)indolin-2ones **1a**, **1i**, and **1n** to predict the binding interaction of these compounds in the active site of both enzymes. These compounds were selected because they showed the highest contrasting α -glucosidase and α -amylase inhibition values (Table 1, entries 1, 9, and 14). In the docking simulation, all the 3,3-di(indolyl)indolin-2-ones **1a**, **1i**, and **1n** recognized the binding pocket of both enzymes correctly. These indolin-2-ones formed stable key interactions with the active sites of both enzymes.

In the case of α -glucosidase, the binding affinities of the three indolin-2-ones is in the order 1a (-7.45 kcal/mol) > 1i (-7.84 kcal/mol) > 1n(-8.26 kcal/mol) which is consistent with the experimental % inhibition trend values 16 \pm 6 < 67 \pm 13 < 94 \pm 3, respectively. The theoretical binding modes of compounds 1a, 1i, and 1n with α -glucosidase are shown in Figure 1. Indolin-2-one 1a formed hydrophobic π - σ interaction with the Trp376. One of the indole rings formed π - π T-shaped interaction with Phe649 and Trp481 while the other indole rings formed π -alkyl with Leu650 and Ala284. Both of the indole rings also formed π -anion interaction with Asp616. From the docking analysis, hydrogen bonds were observed between NH of each indole rings with Met519 (bond length: 2.93 Å) and Asp282 (bond length: 1.88 Å). Indolin-2-one 1i which has an NO₂ and OH groups formed new hydrogen bonds with Leu677 (bond length: 2.34 Å) and Asp404 (bond length: 2.76 Å), respectively, while maintaining the hydrogen bond between the NH of the other indole rings and Asp282 (bond length: 2.06 Å). Additionally, the NO₂ group not only formed a conventional hydrogen bond, but also a non-classical or carbonhydrogen bond with the Ser676. The OH group formed π -lone pair interaction with Trp376. However, it was different from indolin-2-one 1n which did not show the presence of any hydrogen bonds. The p-bromobenzyl group on the indolin-2-one ring in indolin-2-one 1n formed hydrophobic π - π stacking and π -alkyl interactions with Phe649, His674, Trp613, and Trp516 residues. In addition, the benzene ring of the pbromobenzyl group formed a π -anion interaction with Asp518. Besides, both indolin-2-ones 1i and 1n maintained the hydrophobic interaction with Trp376, Leu650, and Ala284 residues.

In the case of docking with α -amylase, the binding affinities of indolin-2-ones were in the order 1i (–8.42 kcal/mol) > 1a (–8.47 kcal/ mol) >1n (–8.75 kcal/mol) which is different from the trend with α -glucosidase. The binding modes of indolin-2-ones **1a**, **1i**, and **1n** with α -amylase are shown in Figure 2. The protein-ligand complex analysis of compound **1a** showed there were two kinds of hydrogen bonds observed on the indolin-2-one ring which were conventional and non-classical hydrogen bonds. The NH of the indolin-2-one ring formed the conventional hydrogen bond with Asp197 (bond length: 1.74 Å) while the carbonyl group of the indolin-2-one ring formed the non-classical hydrogen bond with His101 (bond length: 3.52 Å). The indole rings of compound 1a formed several hydrophobic interactions which were π - σ interaction with Ile235 and Leu162, π -alkyl interaction with Ala198, Leu165, and Leu162. Moreover, there were electrostatic interactions via a π -cation interaction between the indolin-2-one ring and Glu233 then a π -anion interaction between one of the indole rings and His201. From the docking analysis, the carbonyl group of the indolin-2-one ring in compound 1i formed a non-classical hydrogen bond with His101 (bond length: 3.02 Å). One of the indole rings of compound 1i formed π -alkyl, π - σ , and π -anion interactions with Ala198, Leu162, and His 201, respectively. The other indole rings formed π - π T-shaped and π -anion interactions with Tyr62 and GLu233, respectively. Meanwhile, the substitution of the OH group in the indole rings formed hydrogen bonds with Glu233 (bond length: 1.72 Å) and Asp300 (bond length: 1.83 Å). In this receptor, again, compound 1n showed no hydrogen bond but had five types of hydrophobic interaction in its protein-ligand complex. The bromo group of the indolin-2-one ring formed an alkyl hydrophobic interaction with Leu165, while bromo group of the *p*-bromobenzyl of the indolin-2-one ring formed alkyl and π -alkyl interaction with Ile235 and His201, respectively. The *p*-bromobenzyl group also formed π - σ and π -cation interaction with Ile235 and His201, respectively. The indole rings of compound **1n** formed π - π stacking and π - π T-shaped interactions with Trp58 and Tyr62, respectively. Also, the indole rings formed π -anion interaction with Asp300 and Glu233.

4. Conclusions

We have synthesized a series of 3,3-di(indolyl)indolin-2-ones **1a-p** and examined their α -glucosidase and α -amylase inhibitory activities. Overall, the compounds showed desired higher α -glucosidase activities and desired lower α -amylase activities than standard drug AGI acarbose. The inhibitory activity against α -glucosidase varied greatly in comparison to α -amylase concerning the substituents on the core structure. Molecular docking studies showed that the tested compounds interacted with the active sites of both α -glucosidase and α -amylase and the trend in the binding energy values parallel with the % inhibition values. The results suggest that 3,3-di(indolyl)indolin-2-ones, especially indolin-2-one **1i**, are promising AGIs.

Declarations

Author contribution statement

Mardi Santoso, Azminah Azminah, Zaher M. A. Judeh: Conceived and design the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Li Lin Ong, Nur Pasca Aijijiyah, First Ambar Wati, Rose Malina Annuur, Arif Fadlan: Performed the experiments; Analyzed and interpreted the data.

Funding statement

This work was supported by Ministry of Education, Culture, Research, and Technology, Indonesia (WCP Program, PDUPT grant no. 925/PKS/ITS/2021) and Nanyang Technological University (RG142/16).

Data availability statement

Data will be made available on request.

Declaration of interests statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

- A. Mitra, D. Dewanjee, B. Dey, Mechanistic studies of lifestyle interventions in type 2 diabetes, World J. Diabetes 3 (2012) 201–207.
- [2] M. Blair, Diabetes mellitus review, Urol. Nurs. 36 (2016) 27–36 [PMID: 27093761].
- [3] R.A. DeFronzo, E. Ferrannini, L. Groop, R.R. Henry, W.H. Herman, J.J. Holst, F.B. Hu, C.R. Kahn, I. Raz, G.I. Shulman, D.C. Simonson, M.A. Testa, R. Weiss, Type 2 diabetes mellitus, Nat Rev Dis Primers 1 (2015) 15019.
- [4] G. Derosa, P. Maffioli, Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice, Arch. Med. Sci. 8 (2012) 899–906.
- [5] A.F. Afifi, E.M. Kamel, A.A. Khalil, M.F.E. Fawzi, M.M. Houseny, Purification and characterization of oc-amylase from *Penicillium olsonii* under the effect of some antioxidant vitamins, Glob. J. Biotechnol. Biochem. 3 (2008) 14–21.
- [6] Y.-I. Kwon, E. Apostolidis, K. Shetty, Evaluation of Pepper (Capsicum Annuum) for Management of diabetes and Hypertension, J. Food Biochem. 31 (2007) 370–385.

M. Santoso et al.

- [7] Y.-M. Kim, Y.-K. Jeong, M.-H. Wang, W.-Y. Lee, H.-I. Rhee, Inhibitory effect of pine extract on α-glucosidase activity and postprandial hyperglycemia, Nutrition 21 (2005) 756–761.
- [8] M. Yoshikawa, T. Murakami, K. Yashiro, H. Matsuda, Kotalanol, a potent α-glucosidase inhibitor with Thiosugar Sulfonium sulfate structure, from antidiabetic Ayurvedic Medicine Salacia reticulata, Chem. Pharm. Bull. 46 (1998) 1339–1340.
- [9] D.E. Kelley, P. Bidot, Z. Freedman, B. Haag, D. Podlecki, M. Rendell, D. Schimel, S. Weiss, T. Taylor, A. Krol, J. Magner, Efficacy and Safety of acarbose in insulintreated patients with type 2 diabetes, Diabetes Care 21 (1998) 2056–2061.
- [10] S.A. Santos, A.K. Lukens, L. Coelho, F. Nogueira, D.F. Wirth, R. Mazitschek, R. Moreira, A. Paulo, Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype, Eur. J. Med. Chem. 102 (2015) 320–333.
- [11] Y. Song, F. Wu, C. Zhang, G. Liang, G. Zhou, J. Yu, Ionic liquid catalyzed synthesis of 2-(indole-3-yl)-thiochroman-4-ones and their novel antifungal activities, Bioorg. Med. Chem. Lett. 25 (2015) 259–261.
- [12] R. Gali, J. Banothu, R. Gondru, R. Bavantula, Y. Velivela, P.A. Crooks, One-pot multicomponent synthesis of indole incorporated thiazolylcoumarins and their antibacterial, anticancer and DNA cleavage studies, Bioorg. Med. Chem. Lett 25 (2015) 106–112.
- [13] M. Nazir, M.A. Abbasi, Aziz-ur-Rehman, S.Z. Siddiqui, K.M. Khan, Kanwal, U. Salar, M. Shahid, M. Ashraf, M.A. Lodhi, F. Ali Khan, New indole based Hybrid Oxadiazole Scaffolds with N-substituted Acetamides: as potent anti-diabetic agents, Bioorg. Chem. 81 (2018) 253–263.
- [14] S.K. Srivastava, A. Agarwal, P.M. Chauhan, S.K. Agarwal, A.P. Bhaduri, S.N. Singh, N. Fatima, R.K. Chatterjee, Potent 1, 3-disubstituted-9H-pyrido [3, 4-b] indoles as new lead compounds in antifilarial chemotherapy, Bioorg. Med. Chem. 7 (1999) 1223–1236.
- [15] N. Chadha, O. Silakari, Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view, Eur. J. Med. Chem. 134 (2017) 159–184.
- [16] M.Z. Zhang, Q. Chen, G.F. Yang, A review on recent developments of indolecontaining antiviral agents, Eur. J. Med. Chem. 89 (2015) 421–441.
- [17] M. Khan, M. Yousaf, A. Wadood, M. Junaid, M. Ashraf, U. Alam, M. Ali, M. Arshad, Z. Hussain, K.M. Khan, Discovery of novel oxindole derivatives as potent α-glucosidase inhibitors, Bioorg. Med. Chem. 22 (2014) 3441–3448.
- [18] G. Wang, J. Wang, Z. Xie, M. Chen, L. Li, Y. Peng, S. Chen, W. Li, B. Deng, Discovery of 3, 3-di (indolyl) indolin-2-one as a novel scaffold for α-glucosidase inhibitors: in silico studies and SAR predictions, Bioorg. Chem. 72 (2017) 228–233.
- [19] A.R. Karimi, Z. Dalirnasab, G.H. Yousefi, A.R. Akbarizadeh, Synthesis of mono and bis-[3, 3-di (indolyl) indolin-2-ones] and evaluation of their antimicrobial activity, Res. Chem. Intermed. 41 (2015) 10007–10016.
- [20] B.V.S. Reddy, N. Rajeswari, M. Sarangapani, Y. Prashanthi, R.J. Ganji, A. Addlagatta, Iodine-catalyzed condensation of isatin with indoles: a facile synthesis of di (indolyl) indolin-2-ones and evaluation of their cytotoxicity, Bioorg. Med. Chem. Lett. 22 (2012) 2460–2463.
- [21] P. Paira, A. Hazra, S. Kumar, R. Paira, K.B. Sahu, S. Naskar, P. Saha, S. Mondal, A. Maity, S. Banerjee, N.B. Mondal, Efficient synthesis of 3, 3-diheteroaromatic

oxindole analogues and their in vitro evaluation for spermicidal potential, Bioorg. Med. Chem. Lett. 19 (2009) 4786–4789.

- [22] B. Suresh, G. Brahmeshwary, T. Swamy, I. Gopi, V. Ravinder, Efficient synthesis of bis-indolyloxindoles from (phenylimino) indolin-2-ones and 1 H-indole catalyzed by p-toluenesulfonic acid, Russ. J. Gen. Chem. 86 (2016) 1144–1150.
- [23] J. Bergman, N. Eklund, Synthesis and studies of tris-indolobenzenes and related compounds, Tetrahedron 36 (1980) 1445–1450.
- [24] S. Mathavan, K. Kannan, R. Yamajala, Thiamine hydrochloride as a recyclable organocatalyst for the synthesis of bis(indolyl)methanes, tris(indolyl)methanes, 3,3di(indol-3-yl)indolin-2-ones and biscoumarins, Org. Biomol. Chem. 17 (2019) 9620–9626.
- [25] K. Rad-Moghadam, M. Sharifi-Kiasaraie, H. Taheri-Amlashi, Synthesis of symmetrical and unsymmetrical 3, 3-di (indolyl) indolin-2-ones under controlled catalysis of ionic liquids, Tetrahedron 66 (2010) 2316–2321.
- [26] G. Brahmachari, B. Banerjee, Facile and one-pot access of 3, 3-bis (indol-3-yl) indolin-2-ones and 2, 2-bis (indol-3-yl) acenaphthylen-1 (2 H)-one derivatives via an eco-friendly pseudo-multicomponent reaction at room temperature using sulfamic acid as an organo-catalyst, ACS Sustain. Chem. Eng. 2 (2014) 2802–2812.
- [27] J. Kothandapani, S.M.K. Reddy, S. Thamotharan, S.M. Kumar, K. Byrappa, S.S. Ganesan, TBHP Mediated Substrate controlled Oxidative dearomatization of indoles to C2/C3-quaternary indolinones, Eur. J. Org Chem. 2018 (2018) 2762–2767.
- [28] W.Y. Kang, Y.L. Song, L. Zhang, α-Glucosidase inhibitory and antioxidant properties and antidiabetic activity of Hypericum ascyron L, Med. Chem. Res. 20 (2011) 809–816.
- [29] M.A.T. Phan, J. Wang, J. Tang, Y.Z. Lee, K. Ng, Evaluation of α-glucosidase inhibition potential of some flavonoids from Epimedium brevicornum, LWT - Food Sci. Technol. (Lebensmittel-Wissenschaft -Technol.) 53 (2013) 492–498.
- [30] S. Mor, S. Sindhu, Synthesis, Type II diabetes inhibitory activity, antimicrobial evaluation and docking studies of indeno [1, 2-c] pyrazol-4 (1 H)-ones, Med. Chem. Res. 2020 (29) (2020) 46–62.
- [31] C.R. Tysoe, S. Caner, M.B. Calvert, A. Win-Mason, G.D. Brayer, S.G. Withers, Synthesis of montbretin A analogues yields potent competitive inhibitors of human pancreatic α-amylase, Chem. Sci. 10 (2019) 11073–11077.
- [32] I. Miladiyah, J. Jumina, S.M. Haryana, M. Mustofa, Biological activity, quantitative structure–activity relationship analysis, and molecular docking of xanthone derivatives as anticancer drugs, Drug Des. Develop. Ther. 12 (2018) 149–158.
- [33] M.S. Hussain, F. Azam, H.A. Eldarrat, I. Alkskas, J.A. Mayoof, J.M. Dammona, H. Ismail, M. Ali, M. Arif, A. Haque, Anti-inflammatory, analgesic and molecular docking studies of Lanostanoic acid 3-O-α-D-glycopyranoside isolated from *Helichrysum stoechas*, Arab. J. Chem. 13 (2020) 9196–9206.
- [34] R.K. Mohapatra, L. Perekhoda, M. Azam, M. Suleiman, A.K. Sarangi, A. Semenets, L. Pintilie, S.I. Al-Resayes, Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (Mpro): DFT, QSAR, molecular docking, and in silico toxicity analysis, J. King Saud Univ. Sci. 33 (2021) 101315.





	Subr	nit your article	Guide for authors	
Menu	Q Search in this journal			

> Aims and scope

> Editors and staff

Editors and staff

18 April 2023

Heliyon editors and staff

For biographical details about our editors and staff, please see our <u>editors and staff page</u>. For a detailed listing of our advisory board, please see our <u>advisory board page</u>.

Lead editor

Christian Schulz

Senior scientific editor

Pinak Chincholkar

Publisher

On Ching Lo

Editorial team leaders

Sahar Farajnia (Medical sciences)

Harry McGee (Physical and applied sciences)

Sujitha Shiney (Social sciences)

Fiona Ye (Life sciences)

Deputy editorial team leaders

Luca Cannatella

Sahana Krishnan

Associate scientific editors



Guide for authors

Menu	
Senior editorial section manager	-
Echo Yin	
Editorial section managers	
Corey Bugg	
Ruta Cakla	
Rebecca Campbell	
Adlin Neefa Gleetous	
Kimia Golestanian	
Katie Greenwood	
Wenxin Huang	
Selciba Jebastin	
Helen Johnsey Rani	
Roopini Karthikeyan	
Sursha Li	
Jairo Martínez	
Zav McDowell	
Pradipa Mourougane	
Monica Pang	
Hari Priya P.	
Gowsika Rengaraj	
Apoorva Singh	
Natalie Smith	
Sylvia Sun	
Harvey Thibault	
Aishwarya M. Unnikrishnan	
Vigneshwari Uthayakumar	
Xia Wen	
Zoe Wong	
Yunyang Xiao	
Mengpei Yan	
Nisha Yadav	
Kevin Yu	
Jie Zhang	

Naiwen Zhang

Guide for authors

Menu Q	
Elsevier scientific managing editors	
Gayatri Bakshi	
Anirban Basu	
Saswati Basu	
Banu Bayram	
Rauf Bhat	
Stefano Brini	
Natalie Browes	
Elena Brusamarello	
Sebastian Caro Ortiz	
Jessy Ceha	
Rohan Chakrabarty	
Amisha Chauhan	
Chun Mann (Andy) Chin	
Yuan Chu	
Oksana Coban	
Leticya Coelho	
Raffaele Colosimo	
Gabriele Coniglio	
Peter DaBell	
Morteza Davarpanah	
Swathi Desireddy	
Mouboni Dutta	
Jordan Emery	
Bibin Jacob Emmanuel	
Elaine Fabre	
Rong Fan	
Salvatore Federico	
Andréas Flaureau	
Marta Gambucci	
Neha Garg	
Adrià Garriga	
Archita Ghoshal	
Hamid Gilvari	

Guide for authors

Menu	Q
Isabel Hofn	nan
Wouter Ho	ogenboom
Elena Jjaroo	tinska
Ashitha Jos	8
Alise Kalten	iece
Shrikant Ka	wale
Surajit Kaya	d
Madhupras	ad Kigga
Vincent Las	seur
Jing Li	
Chang Liu	
Matt Liu	
Panpan Liu	
Yang Liu	
Joyeeta Lod	h
Vasiliki Lolo	Su la
Nicola Lopi	ZZO
Laura Luzia	
Bulbul Mai	ra
Paresh Maj	hi
Giulia Mau	rizi
Nupur Ano	op Nagar
Mo Chong	Ng
Hakan Niga	ar
Karthik Pan	chabikesan
Francesco F	'api
Jeffrey Poor	1
Said Elias A	. Rahimi
Shuang Qia	10
Ean-Jeong	Seo
Roberto So	
Nikita Sonc	lhi
Flavian Stol	ker Cheregi
Vuandana	Sup

Yuandong Sun

Guide for authors

Menu	Q	
Eleanne va	n Vliet	-
Ioana Vlad	escu	
AnneLies \	/oorhaar	
Inge Werk	nan	
Harry Wilk	inson	
Sarah Willi	ams	
Linghe (Jac	skson) Wu	
Qiang (Joh	nny) Yang	
Sherry Yan	g	
Hamidreza	Yazdani Sarvestani	
Francesco	Zaccaria	
Nurshuhad	da Zainon	
Rui Zhang		
Cong Zhao		
Yi Zheng		



Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.



Submit y	our article
----------	-------------

Guide for authors

Menu Q Search in this journal

Volume 8, Issue 3

March 2022

< Previous vol/issue

Next vol/issue >

Receive an update when the latest issues in this journal are published

Sign in to set up alerts

Research article Open access

The impact of body mass index on the prognostic performance of the Simplified Acute Physiology Score 3: A prospective cohort study

Isabella B.B. Ferreira, Rodrigo C. Menezes, Matheus L. Otero, Thomas A. Carmo, ... Bruno B. Andrade Article e09188

🕅 View PDF 🛛 Article preview 🗸

Research article Open access

Cytotoxicity and ¹H NMR metabolomics analyses of microalgal extracts for synergistic application with Tamoxifen on breast cancer cells with reduced toxicity against Vero cells

Hanaa Ali Hussein, Murni Nur Islamiah Kassim, M. Maulidiani, Faridah Abas, Mohd Azmuddin Abdullah Article e09192

🔁 View PDF 🛛 Article preview 🗸

Research article Open access

Vector learning representation for generalized speech emotion recognition

Sattaya Singkul, Kuntpong Woraratpanya Article e09196

📜 View PDF 🛛 Article preview 👳

Research article Open access

	Submit your article	Guide for authors	
Menu	Q		
Review article	Open access		_
	of solid-state fermentation by micr view and bibliometric analysis	obial biotechnology for bioprocessing of agro-indu	ıstrial wastes from 1970
Levi Yafetto Article e09173			
🚺 View PDF	Article preview 🧹		
Research article	Open access		
Enhanced li	ght olefins production via <i>n</i> -pentan	e cracking using modified MFI catalysts	
Ziyauddin S. Q Article e09181	Qureshi, Palani Arudra, M.A. Bari Siddiqui,	Abdullah M. Aitani, Hassan Alasiri	
🚺 View PDF	Article preview 🗸		
Research article	Open access		
Aerobic exe	rcise with diet induces hormonal, m	netabolic, and psychological changes in postmenop	oausal obese women
Marwa M. Elsa Article e09165	ayed, Ghada E. El Refaye, Ahmed Rabiee, S	ameh Abouzeid, Hany F. Elsisi	
🚺 View PDF	Article preview 🗸		
Research article	Open access		
	ation of polyhydroxyalkanoate prod arious carbon sources	uction capacity, composition and weight synthesiz	ed by Burkholderia cepacia
Julian Hock-C Article e09174	hye Chin, Mohd Razip Samian, Yahaya M.	Normi	
🚺 View PDF	Article preview 🧹		
Research article	Open access		
BEBIG ⁶⁰ Co	HDR brachytherapy source dosime	tric parameters validation using GATE Geant4-base	sed simulation code
Musa Joya, Ha Article e09168	ssan Ali Nedaie, Ghazale Geraily, Mahdi G	horbani, Mahmud Naraqi Arani	
🚺 View PDF	Article preview 🗸		
Research article	Open access		
•	orghum bicolor L.) yield response to r A meta-analysis	ainwater harvesting practices in the semi-arid farn	ning environments of
Friday N.M. Kı Article e09164	ubiku, Ronald Mandumbu, Justice Nyamaı	ngara, George Nyamadzawo	

🔀 View PDF 🛛 Article preview 🧹

t practices


	Submit your article	Guide for authors	
Menu	Q		
Research article	Open access		-
	ndicating HPLC-UV method for the powder, and lozenges	e quantification of anthocyanin in Roselle (<i>Hibiscus</i>	Sabdariffa L.) spray-dried
Nasir Hayat K Article e09177	han, Ibrahim M. Abdulbaqi, Yusrida Darwis	s, Nafiu Aminu, Siok-Yee Chan	
📜 View PDF	Article preview 🗸		
Research article	•		
Technologi	cal insights on the Early-Middle Bro	onze Age pottery of Monte Meana cave (Sardinia, Ita	aly)
Giacomo Pagl Article e09171	ietti, Giuseppa Tanda, Rita Teresa Melis, Ar	nna Musinu, Mariano Casu	
🔀 View PDF	Article preview 🗸		
Research article	Open access		
Assessing at	tentive monitoring levels in dynam	ic environments through visual neuro-assisted app	proach
Yu Fei Li, Sun Article e09067	Woh Lye, Yuvaraj Rajamanickam		
🚺 View PDF	Article preview 🗸		
Research article	Open access		
On the spec	tral radius and energy of signless La	aplacian matrix of digraphs	
Hilal A. Ganie Article e09186	-		
🔀 View PDI	Article preview 🧹		
Research article	Open access		
Wetland mo	onitoring technification for the Ecua	dorian Andean region based on a multi-agent fran	nework
Esteban Valen Article e09054	cia, Iván Changoluisa, Kevin Palma, Patrici	o Cruz, Diana Puga	
🔀 View PDF	Article preview 🗸		
Research article	Open access		
Impact of a from the ob	2 0 0	on student engagement in a Nigerian polytechnic	first-year class: verdict

Oladele O. Campbell, Harrison I. Atagana Article e09191

🚺 View PDF 🛛 Article preview 🗸


Research article Open access

oxicity in rats:




Corrigendum to "Evaluation of in-house cefoxitin screening broth to determine methicillin-resistant staphylococci" [Heliyon 8, (2), (2022), e08950]

Natkamon Saenhom, Rada Kansan, Peechanika Chopjitt, Parichart Boueroy, ... Anusak Kerdsin Article e09149




Husbandry practices and constraints of smallholder dairy production in Dilla Zuriya district, Gedeo Zone, Ethiopia

Sara Endale Hailemariam, Biruh Tesfahun Tezera, Demeke Haile Engidashet Article e09151



Research article Open access


Cucumeropsis mannii seed oil (CMSO) attenuates alterations in testicular biochemistry and histology against Bisphenol a-induced toxicity in male Wister albino rats



🚺 View PDF 🛛 Article preview 🗸


Research article Open access

Techno-economics of coconut coir bioadsorbent utilization on free fatty acid level reduction in crude palmeil



Research article Open access

Emergency management for severe burn (EMSB) course for the nurses in Bangladesh: opportunity and way forward



Article e09148

[View PDF 🔹 Article preview 🗸


Research article Open access

ercial powdered ginger

	Submit your article	Guide for authors	
Menu	Q		
Research article		anagement in academic research laboratories	-
0	E. Gutierrez-Carazo, F. Persico, T. Temple,		
🚺 View PD	F Article preview 🗸		
Research article	e Open access		
	acterial hydrogels based on gelatin/ ation, and preliminary biocompatib	polyvinyl-alcohol and graphene oxide/silver nanoco ility evaluation	onjugates: formulation,
Jorge Luis Pat Article e0914	tarroyo, Javier Cifuentes, Laura N. Muñoz, j 5	uan C. Cruz, Luis H. Reyes	
🚺 View PD	F Article preview 🗸		
Research article	,		
-	g-level human health risk assessmen nts in American Samoa	t for microplastics and organic contaminants in ne	ear-shore marine
Beth Polidorc Article e0910	o, Tiffany Lewis, Cassandra Clement 1		
🚺 View PD	F Article preview 🗸		
Research article			
One-step sy	ynthesis of lead zirconate titanate pa	rticles using a solid-state reaction method	
Darmawan H Article e0912	idayat, Mohammad Taufik, Setianto Setian 5	to	
🚺 View PD	F Article preview 🗸		
Research article	e Open access		
Both Zn bio ZnO nanofe		on pattern in cherry tomato plants are influenced	by the application of
Patricia Alme Article e09130		Fernández, Concepción García-Gomez, Ana Obrador	
🚺 View PD	F Article preview 🗸		
Research article	e Open access		
Assessment Cameroon)		nemicals on bees using the PRIMET model, in the '	Tiko plain (South-West

Daniel Brice Nkontcheu Kenko, Norbert Tchamadeu Ngameni Article e09154

🔀 View PDF 🛛 Article preview 🗸



Charles Obinwanne Okoye, Emmanuel Sunday Okeke, Kingsley Chukwuebuka Okoye, Daniel Echude, ... Chigozie Damian Ezeonyejiaku Article e09143

🔼 View PDF 🛛 Article preview 🗸


ob stress and

	Submit your article	Guide for authors	
Menu	Q		
VICWI D			-
Research article	Open access		
Bioactive ar	nd antimicrobial macro-/micro-nan	oporous selective laser melted Ti–6Al–4V alloy for	biomedical applications
Archana Rajer Article e09122	ndran, Deepak K. Pattanayak 2		
🚺 View PD	F Article preview 🗸		
Research article	Open access		
-	rilinearity with the purpose of advan luring storage periods	nced modeling: towards a more effective analysis of	Pericarpium Citri
Yaping Li, Qir Article e09138	ng Cao, Min He, Xinyue Yang, Weiguo C 3	Cao	
📜 View PD	F Article preview 🧹		
Research article	Open access		
Plaque rem	oval effectiveness of 3D printed der	tal hygiene chews with various infill structures three	ough artificial dog teeth
Su Hyun Lee, Article e09096	Hyun Woo Kim, Hyun Jin Park 5		
📜 View PD	F Article preview 🗸		
Research article	Open access		
Lytic cockta tissue brow		evere burn induced hyper-metabolism through reg	gulating white adipose
Meng Zhang, Article e09128	Peilang Yang, Tianyi Yu, Martin C. Harms 3	en, Xiong Zhang	
🔀 View PD	F Article preview 🧹		
Research article	Open access		
Interactive	effects of citizen trust and cultural v	values on pro-environmental behaviors: A time-lag	study from Indonesia
Irawan, Andri Article e09139			
🔀 View PD	F Article preview 🧹		
Research article	Open access		

Evaluation of inhibitive corrosion potential of symmetrical hydrazine derivatives containing nitrophenyl moiety in 1M HCl for C38 steel: experimental and theoretical studies

Zouhair Lakbaibi, Mohamed Damej, Abdu Molhi, Mohammed Benmessaoud, ... Mohamed Tabyaoui Article e09087

🔀 View PDF 🛛 Article preview 🗸




Cultural adaption and psychometric validation of the Danish Illness Identity Questionnaire (IIQ-DK) in adolescents and emerging adults with type 1 diabetes

Marianne Vie Ingersgaard, Dan Grabowski, Kasper Olesen Article e09109

🚺 View PDF 🛛 Article preview 🧹

ko, Kafa and Sheka



Knowledge, practices, and patterns of data confidentiality among pharmacists in a developing country

Lobna Gharaibeh, Sayer I. Al-Azzam, Karem H. Alzoubi, Reema A. Karasneh, Rana Abu-Farha Article e09115

🚺 View PDF 🛛 Article preview 🗸

ıs from crop residue

Submit your article	Guide for authors	
		O. Aremu
		_
Research article Open access		
Bibliometrics as a promising tool for solving pu	ablication ethics issues	
Vadim N. Gureyev, Nikolay A. Mazov Article e09123		
🔀 View PDF 🛛 Article preview 🗸		
Research article Open access		
Combined distal median nerve block and local	anesthesia with lidocaine:epinephrine for carpal tu	unnel release
Yusef Sallum, Lucian Fodor, George Mărginean, Florian Article e09119	Bodog	
🔀 View PDF 🛛 Article preview 🧹		
Review article Open access		
Plastic recycling and their use as raw material f	or the synthesis of carbonaceous materials	
Rodrigo A. Muñoz Meneses, Gerardo Cabrera-Papamija, Article e09028	Fiderman Machuca-Martínez, Luis A. Rodríguez, Edgar N	Aosquera-Vargas
🔀 View PDF 🛛 Article preview 🧹		
Research article Open access		
Single dose oral pharmacokinetic profile rubraz	xanthone in mice	
Meri Susanti, Riski Darmianti, Yahdiana Harahap, Afrizal Article e09104	Itam, Dachriyanus Hamidi	
🔀 View PDF 🛛 Article preview 🗸		
Research article Open access		
Does information and communication technolo parametric approaches	ogy impede environmental degradation? fresh insi	ghts from non-
Tomiwa Sunday Adebayo, Ephraim Bonah Agyekum, Me Article e09108	hmet Altuntaş, Sadriddin Khudoyqulov, Salah Kamel	
🔀 View PDF 🛛 Article preview 🗸		
Research article Open access		

Peptostreptococcus faecalis sp. nov., new bacterial species isolated from healthy indigenous congolese volunteer

Fatima Mekhalif, Rita Zgheib, Jean Akiana, Melhem Bilen, ... Cheikh Ibrahima Lo Article e09102

🚺 View PDF 🛛 Article preview 🧹

		Submit your article	Guide for authors	
М	enu	Q		e >
ELSEV	Sc	opyright © 2023 Elsevier B.V. or its licensors or contributors. ienceDirect® is a registered trademark of Elsevier B.V.		<mark>≪</mark> RELX™

FEEDBACK Ϙ

also developed by scimago: SCIMAGO INSTITUTIONS RANKINGS

Enter Journal Title, ISSN or Publisher Name

Home Journal Rankings Country Rankings Viz Tools Help About Us

Heliyon 👌

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
Netherlands Universities and research institutions in Netherlands	Multidisciplinary Multidisciplinary	Elsevier BV	69
Media Ranking in Netherlands			
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	24058440	2015-2022	Homepage How to publish in this journal
			c.schulz@cell.com

SCOPE

Heliyon is an all-science, open access journal that is part of the Cell Press family. Any paper reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards, will be considered for publication. Our growing team of dedicated section editors, along with our in-house team, handle your paper and manage the publication process end-to-end, giving your research the editorial support it deserves.

 $\ensuremath{\bigcirc}$ Join the conversation about this journal

FIND SIMILAR JOURNALS

Quartiles

1 Journal of Advanced Research EGY

53% similarity 2 Scientific African NLD 51% similarity 3 Journal of Global Pharma Technology IND


50% similarity Current Pharmaceutical Biotechnology NLD

4

49% similarity options :

5 Saudi Journal of Biological Sciences SAU

48% similarity



Metrics based on Scopus® data as of April 2023

c	Mubbasher munir 6 months ago Hi				
	What is the status of journal in 2022?				
	Is it recognized yet?				
	reply				
	Melanie Ortiz 6 months ago	SCImago Team			
	Dear Mubbasher,				
	Thank you very much for your comment.				
	All the metadata have been provided by Scopus /Elsevier in their last	update sent to			
	SCImago, including the Coverage's period data. The SJR for 2021 was	s released on 11 May			
	2022, We suggest you consult the Scopus database directly to see th	e current index			
	status as SJR is a static image of Scopus, which is changing every da	ay.			
	The Scopus' update list can also be consulted here:				
	https://www.elsevier.com/solutions/scopus/how-scopus-works/cont	tent			
	Best Regards, SCImago Team				
S	Safa 1 year ago				
	Dear Sir,				
	Could you provide me if this journal is included in the Scopus and Clarivate lists?				
	Regards				

Safa



Source details

Heliyon Open Access	CiteScore 2021 4.0	(i)	
Scopus coverage years: from 2015 to Present			
Publisher: Elsevier	SJR 2021	(i)	
E-ISSN: 2405-8440	0.550		
Subject area: (Multidisciplinary)			
Source type: Journal	SNIP 2021	(j)	
	1.270	Ū	
View all documents > Set document alert Save to source list Source Homepage			

CiteScoreTracker 2022 ①


Last updated on 05 April, 2023 • Updated monthly

5.5 = -

61,884 Citations to date 11,184 Documents to date

CiteScore CiteScore rank & trend Scopus content coverage

CiteScore 2021 ~



Calculated off 05 May, 2022

CiteScore rank 2021 🛈

Category	Rank Percentile	
Multidisciplinary — Multidisciplinary	#22/120	82nd

View CiteScore methodology ightarrow CiteScore FAQ ightarrow Add CiteScore to your site \mathscr{S}

Q

About Scopus

- What is Scopus
- Content coverage
- Scopus blog
- Scopus API
- Privacy matters

Language

日本語版を表示する 查看简体中文版本 查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help Tutorials Contact us

ELSEVIER

Terms and conditions iangle Terms Privacy policy iangle Terms

RELX